TGF β 1 Expression Related Gene Polymorphism
ConditionLeprosy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorAswan University
About this trial
Leprosy is one of the oldest human infectious diseases. It is a chronic infectious contagious, granulomatous disease caused by intracellular bacillus.
Mycobacterium leprae, this chronic granulomatous disease presents symptoms that mainly affected the skin, the nervous system and the reticuloendothelial system, also other systems can be affected, such as the upper respiratory tract, bones and joints, eyes and adrenal glands.
TGF- β is a pleiotropic cytokine that employs several functions on different types of cells. The effect of other cytokines may finally modulate the cellular response in the presence of TGF- β, causing a different effect depending on the activation state of the cell involved. In addition, TGF- β promotes the healing of inflamed tissue through the stimulation and regulation of extracellular matrix by fibroblasts, in addition to inducing the proliferation of endothelial cells required for angiogenesis. Thus, TGF- β is able to regulate the expression of other growth factors, increasing their level of activity.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients of both sexes with leprosy.
Age above 18 years.
patients on multidrug therapy of leprosy.
Disqualifiers
Patients with other dermatological disease.
Patients with leprosy reaction.
Pregnancy and lactation.
Patients with autoimmune disease.
Trial population
The study will include (30) leprosy patients and (30) normal control , selected from the outpatient clinic of the Dermatology, Venereology, and Andrology Department, at Aswan University Hospital.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Measurement of TGF- β1 in leprosy patients
Procedure/SurgeryStudy TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Group A: Leprosy Patients1 intervention
Group B: Group B: Healthy People1 intervention
Trial outcomes
Primary outcomes
1
Detection of serum TGF β1
Detection of serum TGF β1 in leprosy patients and Correlate them with different clinical types of leprosy by taking Blood Samples will be collected from the patients to detect TGF β1gene by DNA extraction and SNP genotyping - Genomic DNA will be extracted from peripheral blood samples, then the polymorphism of the TGF β1 gene marker will be selected, The Blood Samples will be collected from the patients before and after treatment with multidrug therapy of leprosy to detect the level of TGF β1 concentrations by ELISA.
Time frame
One YearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov